Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages

  Ellis, Ryan J ^a,d   Wang, Yonghong ^b   Stevenson, Holly ^b   Boufraqech, Myriem ^a   Patel, Dhaval ^a   Nilubol, Naris ^a   Davis, Sean ^b   Edelman, Daniel C ^b   Merino, Maria J ^c   He, Mei ^a   Zhang, Lisa ^a   Meltzer, Paul S ^b   Kebebew, Electron ^a,c  

^a Medical Oncology Branch   (United States)

^b Medical Genetics Branch   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PROTEIN PATCHED;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; CELL GROWTH; CELL MOTION; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE MUTATION; GENOME ANALYSIS; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE RAS; ONCOGENE RET; PRIORITY JOURNAL; PTC GENE; SIGNAL TRANSDUCTION; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOGENESIS; CARCINOMA, PAPILLARY; DNA METHYLATION; FEMALE; GENOME, HUMAN; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 84896709345     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2749     Document Type: Article

References (39)

1. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009; 115(16):3801-3807.
2. Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci. 2010;25(8):1113-1121.
3. Romei C, Elisei R.RET/PTCtranslocations and clinico-pathological features in human papillary thyroid carcinoma. Front Endocrinol (Lausanne). 2012;3:54.
4. Pacini F, CastagnaMG.Approach to and treatment of differentiated thyroid carcinoma. Med Clin North Am. 2012;96(2):369-383.
5. Li X, Abdel-Mageed AB, Kandil E. BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med. 2012;5(4):310-315.
6. Hu S, Liu D, Tufano RP, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer. 2006;119(10): 2322-2329.
7. Xing M, Alzahrani AS, Carson KA, et al. Association betweenBRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493-1501.
8. Eze OP, Starker LF, Carling T. The role of epigenetic alterations in papillary thyroid carcinogenesis. J Thyroid Res. 2011;2011: 895470.
9. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-196.
10. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16(4):168-174.
11. Clark SJ, Melki J. DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene. 2002;21(35):5380-5387.
12. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell. 1999;99(5):451-454.
13. Burri N, Shaw P, Bouzourene H, et al. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest. 2001;81(2):217-229.
14. Wong L, Zhou J, Anderson D, Kratzke RA. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer. 2002;38(2):131-136.
15. Brenet F, Moh M, Funk P, et al. DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One. 2011;6(1): e14524.
16. Ehrlich M.DNAmethylation in cancer: too much, but also too little. Oncogene. 2002;21(35):5400-5413.
17. Lin CH, Hsieh SY, Sheen IS, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 2001;61(10):4238-4243.
18. ToyotaM,Ahuja N, Ohe-ToyotaM,Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96(15):8681-8686.
19. Rechache NS, Wang Y, Stevenson HS, et al. DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J Clin Endocrinol Metab. 2012;97(6):E1004-E1013.
20. Luo JH, Ding Y, Chen R, et al. Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am J Pathol. 2013;182(6):2028-2036.
21. Nischal S, Bhattacharyya S, Christopeit M, et al. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer Res. 2013;73(3): 1076-1085.
22. Kaiser MF, Johnson DC, Wu P, et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumour suppressor genes in multiple myeloma. Blood. 2013;122(2): 219-226.
23. Rodriguez-Rodero S, Fernandez AF, Fernandez-Morera JL, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab. 2013;98(7):2811-2821.
24. Edge SB, American Joint Committee on Cancer, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010:xiv.
25. Mathur A, Moses W, Rahbari R, et al. Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer. 2011;117(19):4390-4395.
26. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology. 2007;148(3):948-953.
27. Wang W, Zhao W, Wang H, et al. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol. 2012;19(1):31-36.
28. O'Neill CJ, Bullock M, Chou A, et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010;148(6):1139-1145; discussion 1145-1146.
29. Hou P, Liu D, Xing M. Endocr Relat Cancer. 2011;18(6):687-697.
30. Vivaldi A, Miasaki FY, Ciampi R, et al. Mol Cell Endocrinol. 2009,307(1-2):142-148.
31. Dom G, Galdo VC, Tarabichi M, et al. 5-Aza-2-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro. Thyroid. 2013;23(3):317-328.
32. Dong X, Korch C, Meinkoth JL. Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells. Endocr Relat Cancer. 2011;18(3):301-310.
33. Sherman EJ, Su YB, Lyall A, et al. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine- refractory thyroid carcinoma. Thyroid. 2013;23(5):593-599.
34. Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121(12): 4700-4711.
35. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013; 368(7):623-632.
36. Yu XM, Schneider DF, Leverson G, Chen H, Sippel RS. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid. 2013;23(10): 1263-1268.
37. Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. Comprehensive microRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid. 2013;23(11):1383- 1389.
38. Gupta N, Dasyam AK, Carty SE, et al. RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular- pattern cancers. J Clin Endocrinol Metab. 2013;98(5): E914-E922.
39. Howitt BE, Jia Y, Sholl LM, Barletta J. Molecular alterations in partially-encapsulated/well-circumscribed follicular variant of papillary thyroid carcinoma. Thyroid. 2013;23(10):1256-1262.